3 / 24
5-FU, 5-fluorouracil; dMMR, mismatch repair deficient; LV, leucovorin; MSI-H, microsatellite instability-high; Nal-IRI, nanoliposomal irinotecan
1997 2007 2011 2013 2015
n
ab
-Paclitaxel
+ gemcitabine
6
FOLFIRINOX
5
Erlotinib +
gemcitabine
4
Gemcitabine
2
S1
3
(Japan)
Nal-IRI +
5-FU/LV
7
5-FU/LV
1
Evolution of Therapy for Metastatic Pancreatic Cancer:
The Story So Far
Pembrolizumab
8
MSI-H/dMMR (US)
1. Glimelius B, et al.
Ann Oncol.
1996;7(6):593-600. 2. Burris HA 3rd, et al.
J Clin Oncol.
1997;15(6):2403-2413. 3. Ueno H, et al.
J Clin Oncol
.
2013;31(13):1640-1648. 4. Moore MJ, et al.
J Clin Oncol.
2007;25(15):1960-1966. 5. Conroy T, et al.
N Engl J Med.
2011;364(19):1817-1825. 6. Von Hoff DD, et
al.
N Engl J Med.
2013;369(18):1691-1703. 7. Wang-Gillam A, et al.
Lancet
. 2016;387(10018):545-557. 8. Le DT, et al.
N Engl J Med
. 2015;372(26):2509-2520.